Association Between Compliance to an Enhanced Recovery Protocol and Outcome After Elective Surgery for Gastric Cancer. Results from a Western Population-Based Prospective Multicenter Study.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
27
6
2019
medline:
6
2
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
The association between compliance to an enhanced recovery protocol (ERAS) and outcome after surgery for gastric cancer has been poorly investigated, particularly in Western patients. The aim of the study was to evaluate whether the rate of adherence to the ERAS program was correlated with outcome and time of discharge. A prospective, observational, multicenter study was designed to be performed at Italian referral centers for gastric surgery. The protocol was discussed and approved by the Italian Research Group on Gastric Cancer. Twenty-three ERAS domains were applied. A multivariate logistic regression was used to assess the association between ERAS compliance and overall and major complication rates. The Poisson regression model (measured as mean ratios) was used to assess the association of ERAS compliance rate and length of stay (LOS). Eight centers participated and 290 subjects with a median age of 73 years were enrolled. The overall rates of adherence to pre-, intra-, and postoperative ERAS items were 69.8%, 60.3%, and 82.5%, respectively. At the multivariate model, there was an association between overall rate of morbidity and an overall ERAS compliance rate greater than 70% (OR 0.413; 95% CI 0.235-0.7240; P 0.002). A similar association was found for major complications (OR 0.328; 95% CI 0.151-0.709; P 0.005). The Poisson regression showed that in patients with ERAS compliance rate >70%, LOS was reduced of approximately 20% (mean ratio 0.812; 95% CI 0.694-0.950; P 0.009). These results suggest a moderate compliance to an ERAS program and a significant association between adherence and outcomes.
Sections du résumé
BACKGROUND
The association between compliance to an enhanced recovery protocol (ERAS) and outcome after surgery for gastric cancer has been poorly investigated, particularly in Western patients. The aim of the study was to evaluate whether the rate of adherence to the ERAS program was correlated with outcome and time of discharge.
METHODS
A prospective, observational, multicenter study was designed to be performed at Italian referral centers for gastric surgery. The protocol was discussed and approved by the Italian Research Group on Gastric Cancer. Twenty-three ERAS domains were applied. A multivariate logistic regression was used to assess the association between ERAS compliance and overall and major complication rates. The Poisson regression model (measured as mean ratios) was used to assess the association of ERAS compliance rate and length of stay (LOS).
RESULTS
Eight centers participated and 290 subjects with a median age of 73 years were enrolled. The overall rates of adherence to pre-, intra-, and postoperative ERAS items were 69.8%, 60.3%, and 82.5%, respectively. At the multivariate model, there was an association between overall rate of morbidity and an overall ERAS compliance rate greater than 70% (OR 0.413; 95% CI 0.235-0.7240; P 0.002). A similar association was found for major complications (OR 0.328; 95% CI 0.151-0.709; P 0.005). The Poisson regression showed that in patients with ERAS compliance rate >70%, LOS was reduced of approximately 20% (mean ratio 0.812; 95% CI 0.694-0.950; P 0.009).
CONCLUSIONS
These results suggest a moderate compliance to an ERAS program and a significant association between adherence and outcomes.
Identifiants
pubmed: 31240434
doi: 10.1007/s00268-019-05068-x
pii: 10.1007/s00268-019-05068-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2490-2498Références
Ann Surg Oncol. 2018 Oct;25(11):3231-3238
pubmed: 30051365
J Gastrointest Oncol. 2015 Feb;6(1):79-88
pubmed: 25642341
Br J Surg. 2014 Sep;101(10):1209-29
pubmed: 25047143
Int J Colorectal Dis. 2014 Mar;29(3):329-41
pubmed: 24337781
Colorectal Dis. 2012 Oct;14(10):e727-34
pubmed: 22594524
Ann Surg. 2008 Aug;248(2):189-98
pubmed: 18650627
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg Oncol. 2018 Aug;25(8):2366-2373
pubmed: 29789971
Int J Surg. 2018 Feb;50:28-34
pubmed: 29288114
Gastric Cancer. 2017 Jan;20(1):20-30
pubmed: 27255288
Eur J Surg Oncol. 2018 Apr;44(4):509-514
pubmed: 29398322
World J Surg. 2013 May;37(5):1082-93
pubmed: 23392451
JAMA Surg. 2018 Mar 1;153(3):270-279
pubmed: 29344622
Oncotarget. 2017 Jun 20;8(43):75699-75711
pubmed: 29088903
J Visc Surg. 2017 Feb;154(1):29-35
pubmed: 27842907
J Laparoendosc Adv Surg Tech A. 2017 Sep;27(9):959-964
pubmed: 27875094
Br J Surg. 2010 Oct;97(10):1547-51
pubmed: 20665480
Ann Surg. 2018 Apr;267(4):623-630
pubmed: 28582271
Ann Surg. 2018 Jun;267(6):1084-1092
pubmed: 28288059
N Engl J Med. 2018 Jun 14;378(24):2263-2274
pubmed: 29742967
Ann Surg. 2015 Jun;261(6):1153-9
pubmed: 25671587
Updates Surg. 2017 Sep;69(3):285-288
pubmed: 28710718
Ann Surg. 2019 Mar;269(3):411-412
pubmed: 30048328
World J Surg. 2017 Aug;41(8):1927-1934
pubmed: 28321553
Gastric Cancer. 2017 Sep;20(5):861-871
pubmed: 28062937
JAMA Surg. 2017 Mar 1;152(3):292-298
pubmed: 28097305
BJS Open. 2017 Nov 09;1(5):128-137
pubmed: 29951615
World J Gastroenterol. 2018 Apr 14;24(14):1562-1578
pubmed: 29662294
Br J Surg. 2017 Aug;104(9):1235-1243
pubmed: 28489249
J Gastrointest Surg. 2017 Apr;21(4):614-621
pubmed: 28120276
World J Surg. 2017 Apr;41(4):1040-1046
pubmed: 27882418
J Gastric Cancer. 2012 Jun;12(2):55-62
pubmed: 22792517
Onco Targets Ther. 2016 Jun 02;9:3345-51
pubmed: 27330314
Surgery. 2018 Dec;164(6):1263-1270
pubmed: 30055788
Clin Nutr. 2003 Jun;22(3):321-36
pubmed: 12765673
J Gastrointest Surg. 2014 Mar;18(3):439-45; discussion 445-6
pubmed: 24420730
Ann Surg. 2004 Dec;240(6):1074-84; discussion 1084-5
pubmed: 15570212
World J Gastroenterol. 2013 Jun 21;19(23):3642-8
pubmed: 23801867
Ann Surg. 2018 Jan;267(1):57-65
pubmed: 28437313
World J Surg Oncol. 2018 Jan 26;16(1):17
pubmed: 29373978
Langenbecks Arch Surg. 2013 Jan;398(1):29-37
pubmed: 23014834
Lancet. 2001 Nov 3;358(9292):1487-92
pubmed: 11705560
J Am Coll Surg. 2018 Mar;226(3):252-258
pubmed: 29277711
Colorectal Dis. 2013 Aug;15(8):1019-25
pubmed: 23470117
Ann Surg. 2018 Jun;267(6):992-997
pubmed: 29303803
World J Surg Oncol. 2017 Nov 23;15(1):207
pubmed: 29169362